Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Integris Baptist Medical Center
mi
from
Oklahoma City, OK
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Integris Baptist Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Medical University of South Carolina
mi
from
Charleston, SC
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Univ of Virginia HSC
mi
from
Charlottesville, VA
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Univ of Virginia HSC
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Swedish Medical Center
mi
from
Seattle, WA
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated:  12/6/2017
Bristol-Myers Squibb
mi
from
Princeton, NJ
Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant
Evaluating Nulojix Long-Term Safety in Transplant
Status: Enrolling
Updated: 12/6/2017
Bristol-Myers Squibb
mi
from
Princeton, NJ
Click here to add this to my saved trials
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/6/2017
Cohen Children's Medical Center of New York
mi
from
New Hyde Park, NY
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery
Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/6/2017
Cohen Children's Medical Center of New York
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Vitamin D and Coronary Calcification Study
A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4
Status: Enrolling
Updated:  12/7/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Vitamin D and Coronary Calcification Study
A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4
Status: Enrolling
Updated: 12/7/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated:  12/7/2017
Clinical Pharmacology of Miami
mi
from
Miami, FL
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated: 12/7/2017
Clinical Pharmacology of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated:  12/7/2017
Orlando Clinical Research Center
mi
from
Orlando, FL
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated: 12/7/2017
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated:  12/7/2017
DaVita Clinical Research
mi
from
Minneapolis, MN
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated: 12/7/2017
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated:  12/7/2017
Prism Clinical Research
mi
from
Saint Paul, MN
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated: 12/7/2017
Prism Clinical Research
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated:  12/7/2017
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901
A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901
Status: Enrolling
Updated: 12/7/2017
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
Podocyte Retinoids
Retinoids for Podocyte Disease
Status: Enrolling
Updated:  12/12/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Podocyte Retinoids
Retinoids for Podocyte Disease
Status: Enrolling
Updated: 12/12/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
A Pilot Study of Allopurinol to Prevent GFR Loss in Type 1 Diabetes.
Status: Enrolling
Updated:  12/13/2017
Joslin Diabetes Center
mi
from
Boston, MA
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
A Pilot Study of Allopurinol to Prevent GFR Loss in Type 1 Diabetes.
Status: Enrolling
Updated: 12/13/2017
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
A Pilot Study of Allopurinol to Prevent GFR Loss in Type 1 Diabetes.
Status: Enrolling
Updated:  12/13/2017
Steno Diabetes Center
mi
from
Gentofte,
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
A Pilot Study of Allopurinol to Prevent GFR Loss in Type 1 Diabetes.
Status: Enrolling
Updated: 12/13/2017
Steno Diabetes Center
mi
from
Gentofte,
Click here to add this to my saved trials
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Knoxville, TN
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Status: Enrolling
Updated:  12/19/2017
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Status: Enrolling
Updated: 12/19/2017
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
Gastrointestinal Adverse Effect Outcomes of De Novo African American Kidney Transplant Recipients Treated With Tacrolimus, Corticosteroids and Mycophenolate Mofetil or Enteric Coated Mycophenolate Sodium
Status: Enrolling
Updated:  12/20/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
Gastrointestinal Adverse Effect Outcomes of De Novo African American Kidney Transplant Recipients Treated With Tacrolimus, Corticosteroids and Mycophenolate Mofetil or Enteric Coated Mycophenolate Sodium
Status: Enrolling
Updated: 12/20/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
Immunogenicity and Efficacy of High-dose Trivalent Inactivated Seasonal Influenza Vaccine (Fluzone High Dose) in Immunocompromised Children and Young Adults.
Status: Enrolling
Updated:  12/21/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
Immunogenicity and Efficacy of High-dose Trivalent Inactivated Seasonal Influenza Vaccine (Fluzone High Dose) in Immunocompromised Children and Young Adults.
Status: Enrolling
Updated: 12/21/2017
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)
Status: Enrolling
Updated:  12/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)
Status: Enrolling
Updated: 12/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment of Masked Hypertension
Treatment of Masked Hypertension
Status: Enrolling
Updated:  12/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Treatment of Masked Hypertension
Treatment of Masked Hypertension
Status: Enrolling
Updated: 12/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
Status: Enrolling
Updated:  12/28/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
Status: Enrolling
Updated: 12/28/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Endothelial Function and Arterio-Venous Fistula Maturation
Endothelial Function and Arterio-Venous Fistula Maturation
Status: Enrolling
Updated:  1/4/2018
San Francisco VA Medical Center
mi
from
San Francisco, CA
Endothelial Function and Arterio-Venous Fistula Maturation
Endothelial Function and Arterio-Venous Fistula Maturation
Status: Enrolling
Updated: 1/4/2018
San Francisco VA Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Endothelial Function and Arterio-Venous Fistula Maturation
Endothelial Function and Arterio-Venous Fistula Maturation
Status: Enrolling
Updated:  1/4/2018
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Endothelial Function and Arterio-Venous Fistula Maturation
Endothelial Function and Arterio-Venous Fistula Maturation
Status: Enrolling
Updated: 1/4/2018
University of California, San Francisco Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Birmingham, AL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
San Diego, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Gainesville, FL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Miami, FL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Orlando, FL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Boise, ID
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Iowa City, IA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Louisville, KY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New Orleans, LA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Boston, MA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Kansas City, MO
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Livingston, NJ
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Livingston, NJ
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Bronx, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials